Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis
- 31 October 1995
- Vol. 17 (4) , 383-390
- https://doi.org/10.1016/s8756-3282(95)00262-6
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosisJournal of Bone and Mineral Research, 1994
- Bone density at various sites for prediction of hip fracturesThe Lancet, 1993
- Effects of 4-amino-1-hydroxybutylidene bisphosphonate on bone biomechanics in ratsJournal of Bone and Mineral Research, 1992
- Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study.BMJ, 1992
- Comparison of the therapeutic potencies of two bisphosphonatesBone, 1992
- The bisphosphonate, alendronate, prevents bone loss in ovariectomized baboonsJournal of Bone and Mineral Research, 1992
- Risks and Benefits of Replacement EstrogenAnnual Review of Medicine, 1992
- A model of lifetime osteoporosis impactArchives of internal medicine (1960), 1991
- The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in ratsJournal of Bone and Mineral Research, 1991
- Predisposition to atherosclerosis in the head, heart, and legs. The Framingham studyJAMA, 1972